Founded in April 1986 to advance psychedelic research and knowledge, MAPS has raised more than $150 million, supported 45 studies, and shaped the ...

MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for ...

This story is part of The Trip, a CPR News series on Colorado’s new psychedelic movement. Read more here. A conference all about psychedelics wrapped up at the Colorado Convention Center in Denver ...

Doblin is the founder and Executive Director of the non-profit research organization the Multidisciplinary Association for Psychedelic Studies (MAPS), founded in 1986 with the goal of researching ...

Rick Doblin, Ph.D., founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS) at PS2023. Psychedelic Science 2025 (PS2025) is inviting trauma therapists and other ...

Reason's Nick Gillespie talked with MAPS founder Rick Doblin about the imminent FDA approval of MDMA- and psilocybin-assisted therapy at the Psychedelic Science conference in Denver.

Psycheceutical Chief Visionary Officer Zappy Zapolin and CEO Chad Harman with MAPS Founder Rick Doblin MIAMI, March 29, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc. ("Psycheceutical" or ...